A detailed history of Susquehanna International Group, LLP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 33,581 shares of CGEM stock, worth $465,432. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,581
Previous 15,486 116.85%
Holding current value
$465,432
Previous $270,000 108.15%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.03 - $20.86 $290,062 - $377,461
18,095 Added 116.85%
33,581 $562,000
Q2 2024

Aug 15, 2024

SELL
$15.63 - $29.35 $298,986 - $561,436
-19,129 Reduced 55.26%
15,486 $270,000
Q1 2024

May 07, 2024

BUY
$10.17 - $19.02 $149,000 - $278,662
14,651 Added 73.39%
34,615 $589,000
Q4 2023

Feb 14, 2024

BUY
$7.89 - $10.23 $55,364 - $71,783
7,017 Added 54.2%
19,964 $203,000
Q3 2023

Nov 14, 2023

SELL
$9.05 - $11.72 $86,590 - $112,136
-9,568 Reduced 42.5%
12,947 $117,000
Q2 2023

Aug 11, 2023

BUY
$8.8 - $13.4 $11,325 - $17,245
1,287 Added 6.06%
22,515 $242,000
Q1 2023

May 16, 2023

BUY
$10.2 - $11.91 $216,525 - $252,825
21,228 New
21,228 $217,000
Q3 2022

Nov 14, 2022

BUY
$11.82 - $15.42 $233,740 - $304,930
19,775 New
19,775 $254,000
Q2 2022

Aug 15, 2022

SELL
$7.31 - $13.55 $110,980 - $205,716
-15,182 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$10.47 - $16.75 $136,780 - $218,822
-13,064 Reduced 46.25%
15,182 $159,000
Q4 2021

Feb 14, 2022

BUY
$15.36 - $25.0 $433,858 - $706,150
28,246 New
28,246 $436,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $632M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.